Walleye Capital LLC bought a new position in Wave Life Sciences Ltd. (NASDAQ:WVE - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 602,441 shares of the company's stock, valued at approximately $4,940,000. Walleye Capital LLC owned approximately 0.48% of Wave Life Sciences at the end of the most recent reporting period.
Other institutional investors have also made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. lifted its stake in Wave Life Sciences by 23.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,512 shares of the company's stock valued at $37,000 after acquiring an additional 856 shares during the last quarter. Profund Advisors LLC acquired a new stake in shares of Wave Life Sciences in the second quarter worth $53,000. Principal Financial Group Inc. acquired a new stake in shares of Wave Life Sciences in the second quarter worth $74,000. Mackenzie Financial Corp lifted its stake in shares of Wave Life Sciences by 13.6% in the second quarter. Mackenzie Financial Corp now owns 15,887 shares of the company's stock worth $79,000 after buying an additional 1,905 shares during the last quarter. Finally, Hsbc Holdings PLC acquired a new stake in shares of Wave Life Sciences in the second quarter worth $104,000. 89.73% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of brokerages have weighed in on WVE. B. Riley increased their price target on shares of Wave Life Sciences from $19.00 to $22.00 and gave the company a "buy" rating in a report on Monday, November 4th. Leerink Partners lifted their target price on Wave Life Sciences from $20.00 to $22.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 16th. Mizuho lifted their target price on Wave Life Sciences from $19.00 to $22.00 and gave the stock an "outperform" rating in a research report on Thursday, November 21st. Truist Financial lifted their target price on Wave Life Sciences from $17.00 to $36.00 and gave the stock a "buy" rating in a research report on Tuesday, November 12th. Finally, Royal Bank of Canada lifted their target price on Wave Life Sciences from $7.00 to $15.00 and gave the stock a "sector perform" rating in a research report on Monday, October 21st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $22.22.
Read Our Latest Analysis on WVE
Wave Life Sciences Stock Performance
Shares of NASDAQ WVE traded up $0.17 during trading hours on Monday, hitting $15.27. 1,467,635 shares of the stock were exchanged, compared to its average volume of 1,113,369. Wave Life Sciences Ltd. has a 1-year low of $3.50 and a 1-year high of $16.74. The company has a market cap of $2.33 billion, a PE ratio of -13.76 and a beta of -1.21. The company's fifty day simple moving average is $12.69 and its two-hundred day simple moving average is $8.23.
Insider Buying and Selling
In other Wave Life Sciences news, major shareholder Plc Gsk purchased 2,791,930 shares of the stock in a transaction dated Friday, September 27th. The shares were bought at an average price of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the transaction, the insider now directly owns 16,775,691 shares in the company, valued at approximately $134,205,528. This trade represents a 19.97 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Chris Francis sold 208,836 shares of the stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $13.67, for a total transaction of $2,854,788.12. The disclosure for this sale can be found here. Insiders sold 453,690 shares of company stock valued at $6,425,883 over the last quarter. Insiders own 29.10% of the company's stock.
About Wave Life Sciences
(
Free Report)
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.
Further Reading
Before you consider Wave Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Wave Life Sciences wasn't on the list.
While Wave Life Sciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
